Scroll

pitavastatin 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antihyperlipidaemic substances, HMG CoA reductase inhibitors	2214	147511-69-1

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: nisvastatin itavastatin pitavastatin calcium hydrate pitavastatin pitavastatin calcium livalo	Pitavastatin competitively inhibits HMG-CoA reductase, which is a rate-determining enzyme involved with biosynthesis of cholesterol, in a manner of competition with the substrate so that it inhibits cholesterol synthesis in the liver. As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is accelerated and then the plasma TC decreases. Further, the sustained inhibition of cholesterol synthesis in the liver decreases levels of very low density lipoproteins. Molecular weight: 421.47 Formula: C25H24FNO4 CLOGP: 3.59 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 90.65 ALOGS: -5.03 ROTB: 8 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

nisvastatin
itavastatin
pitavastatin calcium hydrate
pitavastatin
pitavastatin calcium
livalo

Pitavastatin competitively inhibits HMG-CoA reductase, which is a rate-determining enzyme involved with biosynthesis of cholesterol, in a manner of competition with the substrate so that it inhibits cholesterol synthesis in the liver. As a result, the expression of LDL-receptors followed by the uptake of LDL from blood to liver is accelerated and then the plasma TC decreases. Further, the sustained inhibition of cholesterol synthesis in the liver decreases levels of very low density lipoproteins.

Molecular weight: 421.47
Formula: C25H24FNO4
CLOGP: 3.59
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 90.65
ALOGS: -5.03
ROTB: 8

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
CL (Clearance)	5.85 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	4.60 hours	Lombardo F, Berellini G, Obach RS
BDDCS (Biopharmaceutical Drug Disposition Classification System)	4	Hosey CM, Chan R, Benet LZ
Vd (Volume of distribution)	0.90 L/kg	Lombardo F, Berellini G, Obach RS
BA (Bioavailability)	0.80 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
BA (Bioavailability)	0.60 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
fu (Fraction unbound in plasma)	0.01 %	Lombardo F, Berellini G, Obach RS

Showing 1 to 7 of 7 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
Aug. 3, 2009	FDA	KOWA CO
June 26, 2015	PMDA	Kowa Company, Ltd.

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Myalgia	139.04	17.01	118	6519	146411	63335974
Hepatic function abnormal	94.87	17.01	55	6582	37087	63445298
Cerebral infarction	84.86	17.01	44	6593	23849	63458536
Rhabdomyolysis	49.09	17.01	39	6598	43912	63438473
Renal impairment	40.46	17.01	48	6589	88307	63394078
Liver disorder	40.37	17.01	38	6599	53649	63428736
Haemorrhage subcutaneous	39.59	17.01	14	6623	2969	63479416
Interstitial lung disease	39.41	17.01	40	6597	61868	63420517
Altered state of consciousness	38.49	17.01	27	6610	25203	63457182
Blood creatine phosphokinase increased	33.97	17.01	27	6610	30403	63451982

Showing 1 to 10 of 29 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic function abnormal	126.01	17.63	88	6664	44275	34905904
Interstitial lung disease	116.10	17.63	98	6654	65184	34884995
Myalgia	102.18	17.63	102	6650	84008	34866171
Cerebral infarction	93.53	17.63	61	6691	27394	34922785
Blood creatine phosphokinase increased	83.10	17.63	69	6683	44788	34905391
Rhabdomyolysis	47.41	17.63	62	6690	68101	34882078
Liver disorder	39.93	17.63	40	6712	32957	34917222
Cardiac failure	36.32	17.63	64	6688	91184	34858995
Angina pectoris	34.28	17.63	36	6716	31327	34918852
Visceral pain	30.76	17.63	6	6746	62	34950117

Showing 1 to 10 of 23 entries

Previous1 2 3Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatic function abnormal	210.67	14.55	136	12550	72971	79658731
Myalgia	166.75	14.55	175	12511	185466	79546236
Cerebral infarction	164.56	14.55	98	12588	45578	79686124
Interstitial lung disease	146.07	14.55	130	12556	112470	79619232
Blood creatine phosphokinase increased	101.29	14.55	84	12602	66006	79665696
Rhabdomyolysis	86.73	14.55	94	12592	103037	79628665
Liver disorder	71.61	14.55	72	12614	72345	79659357
Renal impairment	58.08	14.55	96	12590	157687	79574015
Anaemia	47.48	14.55	167	12519	444848	79286854
Cardiac failure	46.31	14.55	86	12600	154756	79576946

Showing 1 to 10 of 67 entries

Previous1 2 3 4 5 6 7Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	C10AA08	CARDIOVASCULAR SYSTEM LIPID MODIFYING AGENTS LIPID MODIFYING AGENTS, PLAIN HMG CoA reductase inhibitors
CHEBI has role	CHEBI:22586	antioxidants
FDA EPC	N0000175589	HMG-CoA Reductase Inhibitor
FDA MoA	N0000000121	Hydroxymethylglutaryl-CoA Reductase Inhibitors
MeSH PA	D000924	Anticholesteremic Agents
MeSH PA	D000963	Antimetabolites
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D019161	Hydroxymethylglutaryl-CoA Reductase Inhibitors
MeSH PA	D000960	Hypolipidemic Agents
MeSH PA	D057847	Lipid Regulating Agents

Showing 1 to 10 of 10 entries

Previous1Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Hypercholesterolemia	indication	13644009
Mixed hyperlipidemia	indication	267434003
Familial hypercholesterolemia	indication	398036000	DOID:13810
Dehydration	contraindication	34095006
Hypothyroidism	contraindication	40930008	DOID:1459
Low blood pressure	contraindication	45007003
Acute infectious disease	contraindication	63171007
Disorder of muscle	contraindication	129565002	DOID:423
Liver function tests abnormal	contraindication	166603001
Impaired renal function disorder	contraindication	197663003

Showing 1 to 10 of 19 entries

Previous1 2Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Show entries

Search:

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	4.05	acidic
pKa2	13.01	acidic
pKa3	13.99	acidic
pKa4	5.11	Basic

Showing 1 to 4 of 4 entries

Previous1Next

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 1MG BASE	LIVALO	KOWA CO	N022363	Aug. 3, 2009	RX	TABLET	ORAL	7022713	Feb. 19, 2024	ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
EQ 2MG BASE	LIVALO	KOWA CO	N022363	Aug. 3, 2009	RX	TABLET	ORAL	7022713	Feb. 19, 2024	ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA
EQ 4MG BASE	LIVALO	KOWA CO	N022363	Aug. 3, 2009	RX	TABLET	ORAL	7022713	Feb. 19, 2024	ADJUNCTIVE THERAPY TO DIET TO REDUCE ELEVATED TOTAL CHOLESTEROL, LOW-DENSITY LIPOPROTEIN CHOLESTEROL, APOLIPOPROTEIN B, TRIGLYCERIDES AND TO INCREASE HDL-C IN ADULT PATIENTS WITH PRIMARY HYPERLIPIDEMIA OR MIXED DYSLIPIDEMIA

Showing 1 to 3 of 3 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Enzyme	P04035	HMDH_HUMAN	INHIBITOR	IC50	8.17	WOMBAT-PK	CHEMBL
Retinoic acid receptor RXR-alpha	Nuclear hormone receptor	P19793	RXRA_HUMAN		Kd	4.88	CHEMBL
Nuclear receptor subfamily 4 group A member 2	Nuclear other	P43354	NR4A2_HUMAN		EC50	6.92	CHEMBL
3-hydroxy-3-methylglutaryl-coenzyme A reductase	Enzyme		HMDH_RAT		IC50	4.98	CHEMBL

Showing 1 to 4 of 4 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
PV9	PDB_CHEM_ID
013206	NDDF
013429	NDDF
147526-32-7	SECONDARY_CAS_RN
173089	MMSL
27200	MMSL
3035	IUPHAR_LIGAND_ID
33902	MMSL
4029463	VUID
4029463	VANDF

Showing 1 to 10 of 27 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Livalo	HUMAN PRESCRIPTION DRUG LABEL	1	66869-104	TABLET, FILM COATED	1.05 mg	ORAL	NDA	32 sections
Livalo	HUMAN PRESCRIPTION DRUG LABEL	1	66869-104	TABLET, FILM COATED	1.05 mg	ORAL	NDA	32 sections
Livalo	HUMAN PRESCRIPTION DRUG LABEL	1	66869-204	TABLET, FILM COATED	2.09 mg	ORAL	NDA	32 sections
Livalo	HUMAN PRESCRIPTION DRUG LABEL	1	66869-204	TABLET, FILM COATED	2.09 mg	ORAL	NDA	32 sections
Livalo	HUMAN PRESCRIPTION DRUG LABEL	1	66869-404	TABLET, FILM COATED	4.18 mg	ORAL	NDA	32 sections
Livalo	HUMAN PRESCRIPTION DRUG LABEL	1	66869-404	TABLET, FILM COATED	4.18 mg	ORAL	NDA	32 sections
ZYPITAMAG	HUMAN PRESCRIPTION DRUG LABEL	1	25208-201	TABLET, FILM COATED	2 mg	ORAL	NDA	26 sections
ZYPITAMAG	HUMAN PRESCRIPTION DRUG LABEL	1	25208-201	TABLET, FILM COATED	2 mg	ORAL	NDA	26 sections
ZYPITAMAG	HUMAN PRESCRIPTION DRUG LABEL	1	25208-202	TABLET, FILM COATED	4 mg	ORAL	NDA	26 sections
ZYPITAMAG	HUMAN PRESCRIPTION DRUG LABEL	1	25208-202	TABLET, FILM COATED	4 mg	ORAL	NDA	26 sections

Showing 1 to 10 of 14 entries

Previous1 2Next